Skip to main content
. 2016 Feb 24;18(8):1120–1128. doi: 10.1093/neuonc/now023

Fig. 6.

Fig. 6.

Efficacy of local delivery of FGK45 in bRiTs-G3 models developed with severe combined immunodeficiency (SCID) mice and comparison of efficacy of vaccination therapy and local delivery of FGK45 in NSCL61 and bRiTs-G3 models. (A) SCID mice (n = 5) were implanted with bRiTs-G3 cells and treated with convection-enhanced delivery (CED) of 10 µg FGK45 (in 10 µL PBS) on day 5. Control mice received CED of 10 µg IgG (in 10 µL PBS). FGK45-treated SCID mice survived slightly longer than IgG-treated SCID mice, but the difference was not significant (P = .1021). (B) Groups of mice treated with IgG (100 µg, control) or FGK45 (100 µg) added to tumor lysate-based vaccination (n = 5 for each group) or those treated with local delivery of IgG (10 µg, control) or FGK45 (10 µg) (each group, n = 5) were compared. Local delivery of FGK45 was more effective than vaccination therapy of FGK45 in both models (B: NSCL61, P = .0040, C: bRiTs-G3, P = .0018).